PALI · Palisade Bio, Inc.
$2.11
+0.05 (+2.43%)
At close · Aug 21
Market Cap
$376.42M
Shares
174.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.06
Open$2.14
Day$2.03–2.15
52W close$0.54–2.80
Avg vol 30d2.1M
Short int33.7M · 19.3% float · 14.6d
Short vol69%
DataApr 2024–Aug 2026
Filing10-Q · Aug 10
Raw chart and full-history price indicators begin at the captured split on Apr 8, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
+4%
above
RSI (14)
51
neutral
MACD trend
Positive
52-week position
67%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+16%
trailing
YTD return
−12%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+28% holders QoQ · +49 funds added
Insider flow
Distributing
Net -$159.7K over 90 days · 67% sells
Short interest
Falling
19.34% of float · ▼ -9.0% MoM · 14.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
123 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+1500%
Y/Y
EPS growth
+97%
Y/Y
Free cash flow
$-10.8M
Balance sheet
$133.3M
net cash
Quant / Vol
risk profile
Volatility
115%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
67%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+28% holders QoQ · +49 funds added
Insider flow
Distributing
Net -$159.7K over 90 days · 67% sells
Short interest
Falling
19.34% of float · ▼ -9.0% MoM · 14.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
123 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 67%
Range high $3
vs 200-day avg +6%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PALI
this stock
Palisade Bio, Inc.
|
$376.42M | -12.3% | +1500.4% | — | 19.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Apr 8, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PALI | -4.2% | +2.0% | +16.4% | +8.7% | -12.3% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -2.2% | -1.3% | +5.2% | +6.6% | -24.2% |
Key facts
CIK
1357459
CUSIP
696389402
13F (30d)
122 filings
121 filers
Visit website
Investor relations